35 Stocks Moving In Monday’s Mid-Day Session
Gainers
ZIVO Bioscience, Inc. (NASDAQ: ZIVO) jumped 145% to $6.86 after declining around 17% on Friday.
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi’s Pemphigus Trial Disappointment, Humanigen’s COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 8)
Immuneering Q2 Sales $660.00K Up From $480.80K YoY
Immuneering (NASDAQ:IMRX) reported $660.00 thousand in sales this quarter. This is a 37.27 percent increase over sales of $480.80 thousand the same period last year.
Immuneering Q2 EPS $(1.61) Down From $(0.73) YoY
Immuneering (NASDAQ:IMRX) reported quarterly losses of $(1.61) per share. This is a 120.55 percent decrease over losses of $(0.73) per share from the same period last year.
Cowen & Co. Initiates Coverage On Immuneering with Outperform Rating
Cowen & Co. analyst Yaron Werber initiates coverage on Immuneering (NASDAQ:IMRX) with a Outperform rating.
Guggenheim Initiates Coverage On Immuneering with Buy Rating, Announces Price Target of $42
Guggenheim analyst Michael Schmidt initiates coverage on Immuneering (NASDAQ:IMRX) with a Buy rating and announces Price Target of $42.